EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Gleason score 3+3=6 prostatic adenocarcinoma is not benign and the current debate is unhelpful to clinicians and patients

Hemamali Samaratunga, Lars Egevad, John Yaxley, Joanna Perry-Keene, Ian Le Fevre, James Kench, Admire Matsika, David Bostwick, Kenneth Iczkowski, Brett Delahunt

Pathology · 2024-02 · 56 (1) · 33-38

DOI: 10.1016/j.pathol.2023.10.005 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pathology, 2024-02. Verfasst von Hemamali Samaratunga und 9 weiteren Autor:innen. Beteiligte Einrichtung: Aquesta Uropathology, Brisbane, Qld, Australia; University of Queensland, Brisbane, Qld, Australia. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Carcinoma, Adenocarcinoma. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 39 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Prostate adenocarcinoma is a common malignancy associated with a significant morbidity and mortality. In both prostate biopsies and radical prostatectomy specimens Gleason scoring informs both treatment and outcome prediction. The current convention is that in needle biopsies, Gleason patterns 3, 4 and 5 are considered to be malignant. Despite this there is debate as to whether or not Gleason score (GS) 3+3=6 should be diagnosed as cancer due to potential over-treatment and the psychological impact on patients. It is apparent that GS 3+3=6 is indolent disease with a low risk of metastasis. However, it does have the histological features of malignancy and is capable of infiltrating the prostate gland, extraprostatic extension, and metastatic spread. Furthermore GS 3+3=6 carcinoma has immunohistochemical and molecular genetic features similar to those of higher grade prostatic carcinoma. If GS 3+3=6 tumour is considered benign, the question arises should a benign label be given to the Gleason pattern 3 component of tumour that includes Gleason patterns of higher grade? This would seem a logical step as GS 3+3=6 cancers and the pattern 3 component in cancers with multiple patterns are morphologically identical. If pattern 3 is considered to be benign, then Gleason scoring would be limited to 4+4=8, 4+5=9, 5+4=9 and 5+5=10 which is clearly inappropriate. The correct strategy to address potential over-treatment of patients with low-grade cancer is clinician and patient education, not the recalibration of Gleason grading to reclassify malignant tumours as benign.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsCarcinomaAdenocarcinomaMaleHumansNeoplasm GradingBiopsy, NeedleProstatectomy

Stichwörter der Autor:innen

Gleason scoreProstateadenocarcinomaprognosis

Autor:innen und Institutionen

  • Aquesta Uropathology, Brisbane, Qld, Australia; University of Queensland, Brisbane, Qld, Australia.
  • Department of Oncology and Pathology, Karolinska Instituet, Stockholm, Sweden.
  • University of Queensland, Brisbane, Qld, Australia; Wesley Hospital, Brisbane, Qld, Australia.
  • Aquesta Uropathology, Brisbane, Qld, Australia; Sunshine Coast University Hospital, Sunshine Coast, Qld, Australia.
  • Aquesta Uropathology, Brisbane, Qld, Australia.
  • Royal Prince Alfred Hospital and University of Sydney, Sydney, NSW, Australia.

Zitieren

APA

Samaratunga, H., Egevad, L., Yaxley, J., Perry-Keene, J., Le Fevre, I., Kench, J., Matsika, A., Bostwick, D., Iczkowski, K., & Delahunt, B. (2024). Gleason score 3+3=6 prostatic adenocarcinoma is not benign and the current debate is unhelpful to clinicians and patients. Pathology, 56(1), 33-38. https://doi.org/10.1016/j.pathol.2023.10.005

Vancouver

Samaratunga H, Egevad L, Yaxley J, Perry-Keene J, Le Fevre I, Kench J, et al. Gleason score 3+3=6 prostatic adenocarcinoma is not benign and the current debate is unhelpful to clinicians and patients. Pathology. 2024;56(1):33-38. doi:10.1016/j.pathol.2023.10.005

BibTeX
@article{Samaratunga2024,
  author = {Samaratunga, Hemamali and Egevad, Lars and Yaxley, John and Perry-Keene, Joanna and Le Fevre, Ian and Kench, James and Matsika, Admire and Bostwick, David and Iczkowski, Kenneth and Delahunt, Brett},
  title = {Gleason score 3+3=6 prostatic adenocarcinoma is not benign and the current debate is unhelpful to clinicians and patients},
  journal = {Pathology},
  year = {2024},
  volume = {56},
  number = {1},
  pages = {33--38},
  doi = {10.1016/j.pathol.2023.10.005}
}
Kostenlos starten →